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Summary Expression of the equilibrative, S-(p-nitrobenzyl)-6-thioinosine (NBMPR)-sensitive nucleoside
transporter (es), a component of the nucleoside salvage pathway, was measured during unperturbed growth
and following exposure to various antimetabolites at growth-inhibitory concentrations. The probe 5-
(SAENTA-x8)-fluorescein is a highly modified form of adenosine incorporating a fluorescein molecule. It binds
with high affinity and specificity to the (es) nucleoside transporter at a 1:1 stoichiometry, allowing reliable
estimates of es expression by flow cytometry. Using a dual labelling technique which combined the vital DNA
dye Hoechst-33342 and 5-(SAENTA-x8)-fluorescein, we found that surface expression of es approximately
doubled between GI and G2 + M phases of the cell cycle. To address the question of whether es expression
could be modulated in cells exposed to drugs which inhibit de novo synthesis of nucleotides, cells were exposed
to antimetabolite drugs having different modes of action. Hydroxyurea and 5-fluorouracil (5-FU), which
inhibit the de novo synthesis of DNA precursors, produced increases in the expression of es. In contrast,
cytosine arabinoside (ara-C) and aphidicolin, which directly inhibit DNA synthesis, produced no significant
increase in es expression. Thymidine (TdR), which is an allosteric inhibitor of ribonucleotide reductase that
depletes dATP, dCTP and dGTP pools while repleting the dTTP pool, had no significant effect on es
expression. These data suggest that surface expression of the es nucleoside transporter is regulated by a
mechanism which is sensitive to the supply of deoxynucleotides. Because 5-FU (which specifically depletes
dTTP pools) causes a large increase in expression whereas TdR (which depletes all precursors except dTTP)
does not, this mechanism might be particularly sensitive to dTTP pools.
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The salvage of preformed nucleosides requires their permea-
tion across the plasma membrane and subsequent metabolic
trapping by conversion to ribo- and deoxyribonucleotides.
The efficiency of the nucleoside salvage pathway is believed
to have major effects on sensitivity to a wide range of
antimetabolite drugs. Modified nucleosides such as cytosine
arabinoside (ara-C) and 2-chlorodeoxyadenosine are taken
up by the salvage pathway, and low levels of activity are
therefore a potential mechanism of drug resistance. In con-
trast the toxicity of agents that inhibit the de novo synthesis
of DNA precursors, such as methotrexate and 5-fluorouracil
(5-FU), can be reversed by uptake of thymidine from the
extracellular fluid, so that increased nucleoside salvage
capacity could result in treatment failure.
Preformed nucleosides enter mammalian cells via a number
of nucleoside transport (NT) systems (Plagemann et al.,
1988). In mammalian cells, the equilibrative facilitated diff-
usion NT process (es) is widely distributed and sensitive to
inhibition by S-(p-nitrobenzyl)-6-thioinosine (NBMPR) (Cass
et al., 1974; Wiley et al., 1983; Belt et al., 1993). In various
cell types, es can be coexpressed with other different NT
processes, such as the NBMPR-insensitive equilibrative NT
(ei) (Belt, 1983; Crawford et al., 1990; Crawford and Belt,
1991), or the Na +-linked concentrative NT process (cij)
(Crawford et al., 1990; Crawford and Belt, 1991; Roden et
al., 1991). The es process is of high capacity and low affinity
and is followed by phosphorylation by kinases with low
capacity and high affinity for the nucleoside which enters the
cell. Kinetic and computer analysis suggest that the transport
of nucleosides is rate limiting at low (< 1IM) concentrations
of extracellular nucleosides (Wiley et al., 1985; White et al.,
1987). Nucleoside levels of this order occur in human serum
(Nottebrock and Then, 1977), suggesting that nucleoside
transporter expression might be an important rate-limiting
step in the cellular utilisation of nucleosides by the salvage
pathway in man.
Traditionally nucleoside transport and uptake have been
studied using radiolabelled compounds. The development by
Agbanyo et al. (1990) of a highly modified analogue of
adenoside, 5'-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5'-thioaden-
osine (SAENTA), which is capable of forming conjugates
with fluorescent dyes has allowed the use of flow cytometry
as an alternative analytical technique. Recently Jamieson et
al. (1993) described the use of 5-(SAENTA-x8)-fluorescein,
which is sufficiently sensitive to detect low levels of es exp-
ressed by peripheral blood leukaemic blasts. Specificity of
binding can be confirmed by displacement with the non-
fluorescent es inhibitor, NBMPR. Analysis of es expression
by 5-(SAENTA-x8)-fluorescein using flow cytometry enables
the investigation of ligand-cell interactions, and determinat-
ion of nucleoside transporter expression in subsets of cells
defined by additional parameters such as laser light scatter or
surface immunofluorescence. In this paper we report the
expression of es throughout the cell cycle, and the
modulating effects of antimetabolite drugs.
Materials and methods
Chemicals
5-(SAENTA-x8)-fluorescein was synthesised as previously
described (Jamieson et al., 1993). Aphidicolin (APC), ara-C,
5-FU, thymidine (TdR), cycloheximide, NBMPR, and
Hoechst-33342 were purchased from Sigma (St Louis, MO,
USA) and hydroxyurea from Calbiochem (La Jolla, CA,
USA). Media, phosphate-buffered saline (PBS), antibiotics
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and trypsin were purchased from Gibco (Grand Island, NY,
USA). Plasticware was purchased from Falcon (Bedford,
MA, USA).
Cell Culture
The human bladder cancer cell line, MGH-U1, the human
acute lymphoblastic leukaemia cell line, CEM and the acute
myeloid leukemia cell line, AML2 were maintained in a-
minimum essential media (a-MEM), and the acute lympho-
blastic cell line, Jurkat, in RPMI-1640 medium. All media
were supplemented with 0.01% streptomycin, 0.01% peni-
cillin and 10% fetal calf serum (Whittaker, Walkersville,
MD, USA and PA Biologicals, Sydney, Australia). The cells
were grown at 37°C in a 5% carbon dioxide humidified
atmosphere (Erlichman and Vidgen, 1984; Pressacco and
Erlichman, 1993) and subcultured twice weekly until passage
20.
5-(SAENTA-x8)-fluorescein binding assay
Cells were resuspended at a concentration of 1 x 106ml-' in
phenol red-free medium, and labelled with 5 nM 5-(SA-
ENTA-x8)-fluorescein at room temperature (RT) for 10min
in the dark, in the presence or absence of 2.5 iLM NBMPR as
previously described (Jamieson et al., 1993). Fluorescence
was measured using an Epics Elite flow cytometer (Coulter,
Hialeah, FL, USA) fitted with a 488 nm argon laser, collect-
ing emission with a bandpass filter centred at 525 nm. Simul-
taneous measurement of 5-(SAENTA-x8)-fluorescein binding
and cellular DNA content was done using an air-cooled
helium-cadmium laser emitting at 325 nm to excite the vital
DNA dye Hoechst-33342. Forward angle and right-angle
scatter signals were used for live cell gating and a minimum
of 10000 viable cells were examined for each sample.
Results
As previously reported (Jamieson et al., 1993), 5-(SAENTA-
x8)-fluorescein bound to the membranes of viable cells from
all four cell lines with high affinity, achieving saturation at a
concentration of approximately 5 nM (data not shown).
Coincubation with a 500-fold excess of the non-fluorescent
compound NBMPR, a tight binding inhibitor of es, reduced
cell fluorescence to that of background autofluorescence,
confirming that 5-(SAENTA-x8)-fluorescein is a specific,
high-affinity ligand for es.
Dual staining with 5-(SAENTA-x8)-fluorescein and the
vital DNA dye Hoechst-33342 enabled the investigation of
changes in es expression throughout the cell cycle. Because
competition was observed between Hoechst-33342 uptake
and 5-(SAENTA-x8)-fluorescein binding, the concentration of
Hoechst-33342 used was reduced from 10 to 1.0 iLM, and the
concentration of 5-(SAENTA-x8)-fluorescein increased from
5 to 80 nM. Despite this relatively high 5-(SAENTA-x8)-
fluorescein concentration, binding was shown to be specific
as demonstrated by NBMPR displacement. As shown in
Figure 1, there was an increase in es expression during
S-phase, which persisted into G2 phase.
Modulation of es expression was investigated using anti-
metabolite drugs with differing mechanisms of action. Each
drug was used at a concentration that was growth inhibitory
while maintaining cell viability as assessed by the laser light
scattering pattern observed by flow cytometry. For the
cytotoxic agents 5-FU and ara-C this corresponded approx-
imately to the IC5o concentration as determined by clono-
genic survival. The modulation of es expression on the sur-
face of MGH-Ul cells by 5-FU, ara-C, TdR and APC
following a 24 h exposure is shown in Figure 2. Ara-C, TdR
and APC had no appreciable effect on es expression, whereas
5-FU and hydroxyurea increased the expression of es, by up
to 10-fold with 40 tLM 5-FU in MGH-U1 cells. The effects of
hydroxyurea were further investigated using MGH-Ul,
CEM, Jurkat, and AML2 cells (Figure 3). In all of the cell
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Figure 1 (a) Cell cycle relationship of es expression in CEM
human T-lymphoblasts, using dual labelling with 5-(SAENTA-
x8)-fluorescein and Hoechst-33342. (b) Specificity control using
500 x excess NBMPR.
lines, 24 h exposure to 50 and 200 tLM hydroxyurea increased
es expression. This effect was reversed by simultaneous treat-
ment with the protein translation inhibitor cycloheximide
(2.5 tsg ml-'), indicating that the effect of hydroxyurea is to
increase de novo synthesis of es, rather than to cause its
redistribution in membranes. Treatment of CEM cells with
2.5 jig ml-' cycloheximide alone resulted in a decrease in es
expression to 29% of control value at 24 h, and 6% of
control at 48 h, giving a half-life of approximately 12 h for es
on the cellular membrane.
Exponentially growing cells incubated in either nucleoside-
free or nucleoside-rich media for 48 h showed no difference
in es expression or modulation. Thus, preformed nucleosides
did not alter the expression of es, consistent with the lack of
modulation of es expression observed with TdR in our
studies.
Discussion
Mammalian cells possess several specific transport elements
that mediate both the entry and exit of nucleosides (Paterson
et al., 1981; Wohlhueter and Plagemann, 1982). Substrate
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Figure 2 Effects of anti-cancer agents on es expression in MGH-
Ul cells. Drugs were exposed for 24 h at the concentrations
indicated. Each point represents the mean of at least three
separate experiments ± s.d.
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Figure 3 Effects of hydroxyurea on es expression exposed for
24 h in various cell lines. Each point represents the mean of at
least three separate experiments ± s.d.
specificity for es is quite broad in that structurally diverse
molecules, including purine and pyrimidine ribonucleosides
and deoxyribonucleosides, synthetic nucleosides and nucleo-
side analogues, can be transported. The relevance of es to
cancer treatment has two aspects: reduced expression might
be associated with resistance to treatment using modified
nucleosides that enter cells via es, such as ara-C (Wiley et al.,
1985) or 2-chloro-2'-deoxyadenosine, whereas the increased
capacity to salvage preformed nucleosides from extracellular
fluid is believed to confer resistance to other antimetabolite
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drugs, such as methotrexate (MTX) (Cabral et al., 1984;
Wadler et al., 1987) and 5-FU (Grem and Fischer, 1989),
that inhibit the de novo synthesis of DNA precursors.
Attempts have been made to exploit nucleoside salvage path-
ways in order to improve chemotherapy results. For example,
potentiating the uptake and phosphorylation of ara-C by
depleting the endogenous dCTP pool with hydroxyurea
(Walsh et al., 1980; Rauscher and Cadman, 1983) or
inhibiting these processes with agents such as dipyridamole
to increase the effectiveness of MTX or 5-FU (Cabral et al.,
1984; Wadler et al., 1987; Grem and Fischer, 1989).
In this paper we have confirmed that 5-(SAENTA-x8)-
fluorescein is a high-affinity, specific ligand for es. Because we
postulated that surface expression of nucleoside transporter
might increase during DNA synthesis we examined its cor-
relation with cell cycle distribution using dual labelling with
5-(SAENTA-x8)-fluorescein and the vital DNA dye Hoechst-
33342. As shown in Figure 1, there was an approximately
2-fold increase in es during the cell cycle. Similar results have
been reported in HeLa cells synchronised by mitotic detach-
ment, in which the number of [3HI NBMPR binding sites
increased 2- to 3-fold as cells progressed from GI phase
through S-phase of the cell cycle (Cass et al., 1979). The
comparatively small increase in es during the cell cycle argues
against the expression being regulated to meet a demand for
DNA precursors during S-phase. Using the protein synthesis
inhibitor cycloheximide we obtained a half-life for es in the
plasma membrane of 12 h. This agrees closely with the half-
life of loss of nucleoside transport capacity observed during
induced differentiation of HL60 cells (Chen et al., 1986). If
the synthesis of nucleoside transporter were indeed syn-.
chronised with the onset of S-phase, as we had originally
postulated, this comparatively long half-life might explain
why the increase in es expression during the cell cycle is only
approximately 2-fold.
Expression of es can be modulated by treatment with
growth-inhibitory concentrations of certain antimetabolites.
Of particular interest is the increase in es expression follow-
ing exposure to hydroxyurea, which inhibits ribonucleotide
reductase and depletes deoxynucleotide triphosphate pools
generally, and to 5-FU, which depletes dTTP. These inc-
reases were large compared to the natural increase in es
expression during the cell cycle, and are therefore unlikely to
be explained simply by a build up of cells in S-phase.
Thymidine itself is an allosteric inhibitor of ribonucleotide
reductase, and depletes dATP, dCTP and dGTP while in-
creasing the dTTP pool, and treatment with this agent pro-
duced no increase in es expression. Aphidicolin and ara-C,
which directly inhibit DNA synthesis, also had no significant
effect on es expression.
We interpret these data as showing that cells can actively
regulate the expression of es on the surface membrane, and
that this regulation involves a feedback control which is
sensitive to the supply of deoxynucleotides, particularly
dTTP. It is well established that depletion of DNA pre-
cursors can increase the activity of salvage pathways, but this
is usually considered to be due to an effect on the specific
kinases which phosphorylate nucleosides, thereby trapping
them inside the cell. Although it has been suggested that the
efficiency of es is such that the initial rate of uptake is
unlikely to be rate limiting for the salvage pathway, the large
increases in es expression following exposure to 5-FU or
hydroxyurea in vitro suggest that under some circumstances
its capacity might be inadequate for maintenance of DNA
synthesis. This up-regulation of es has important implications
as a possible adaptive mechanism leading to antimetabolite
drug resistance in cancer patients. Further studies should
therefore be aimed at elucidating the mechanisms by which es
expression is regulated in vitro and determining the relation-
ship between the levels of expression and the response to
chemotherapy in cancer patients. Because of the specificity
and ease of use, flow cytometric measurement of fluorescent
derivatives of SAENTA appears to offer a powerful new
method for studying the role of es in response to anti-
metabolite drugs.Modulation of nucleosid transporter
J Pressacco etal
942
Abbreviations
NT, nucleoside transporter; es, equilibrative NBMPR-sensitive
nucleoside transporter; NBMPR, S-(p-nitrobenzyl)-6-thioinosine;
SAENTA, 5'-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5'-thioadenosine;
ara-C, cytosine arabinoside; ara-CTP, ara-C triphosphate; 5-FU,
5-fluorouracil; TdR, thymidine; APC, aphidicolin: dTTP, thy-
midine-5'-triphosphate; dTMP, thymidine-5'-monophosphate, thy-
midylate; dATP, 2-deoxyadenosine-5'-triphosphate; dCTP, 2-deoxy-
cytidine-5'-triphosphate; dGTP, 2-deoxyguanosine-5'-triphosphate.
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